Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from October 2020.
Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from October 2020.
5. Nivatrotamab Granted Orphan Drug Status for Pediatric Neuroblastoma
The FDA granted an orphan drug designation and rare pediatric disease designation to the bispecific antibody nivatrotamab for the treatment of patients with neuroblastoma, according to an announcement from Y-mAbs Therapeutics, Inc.
4. We Honor Oncology Nurses for Their Dedication
This letter from our Chairman and Founder, Mike Hennessy, Sr., about the recent Extraordinary Healer and Finest Hour awards explores why nurses should be celebrated year-round for their dedication to patients with cancer.
3. Frontline Treatment Decisions Are Crucial in Myeloma
In recent years, 5-year survival rates have increased for patients with myeloma. However, the majority of patients will still relapse after their treatment — some faster than others – highlighting the importance of establishing the longest possible remission the first time around.
2. A Smiling Nurse Makes All the Difference in Pediatric Oncology
Being hospitalized for cancer can be a frightening experience for a child, but here, we take a look at how a friendly and approachable nurse can make all the difference.
1. Chemo Cheat Sheets Help Nurses During Drug Delivery
In this episode of The Vitals, Oncology Nursing News’ podcast, we spoke with Kellie Zeichner, RN, BSN, OCN, an oncology nurse at the Rutgers Cancer Institute of NJ, about how she worked with an interdisciplinary team to create reference sheets containing key information about oncology drugs.
Thanks for reading!
FDA Approves Encorafenib Plus Cetuximab and Chemo in BRAF V600E-Positive Metastatic CRC
Published: December 20th 2024 | Updated: December 20th 2024The FDA has granted approval for the use of encorafenib in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer harboring a BRAF V600E mutation.